Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...

background and objective: non-specific granulomatous prostatitis is an uncommon diffuse inflammatory condition of the prostate. it is important because it may be mistaken for prostatic carcinoma. the aim of the study was to determine the prevalence of non-specific granulomatous prostatitis (nsgp) and comparing the results of transrectal ultrasonography, serum prostate specific antigen (psa) and...

background: stereotactic body radiotherapy (sbrt) has emerged as an effective treatment for localized prostate cancer. however, prostate-specific antigen (psa) kinetics after sbrt has not been well characterized. the objective of the current study is to analyze the rate of psa decline and psa nadir following hypofractonated sbrt in localized prostate cancer. materials and methods: from 2008 to ...

conclusions results showed that whereas knowledge by itself cannot guarantee men’s participation in prostate cancer screenings, perceived barriers can play an important role in discouraging men from cancer screening participation. therefore, designing programs to address these barriers is very important. results the most common barriers to screening for prostate cancer were a lack of knowledge ...

Background: Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling. Methods: This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with loc...

We compared two recently introduced commercial assays (CanAg and Immulite) for measuring free prostate-specific antigen (f-PSA), total PSA (t-PSA), and the ratio of t-PSA/f-PSA (f-PSA%) in control materials and sera of 54 healthy men, 50 patients with benign prostatic hyperplasia (BPH), and 45 patients with prostate cancer (PCa). The lower detection limits for f-PSA were 0.038 microgram/L and 0...

Cancer is among the leading causes of death and an important barrier to improving life expectancy globally. Prostate cancer second most common in men worldwide. The detection biomarkers body fluids key topic for diagnosis prognosis prostate cancer. Despite advances methods, therapeutic agents new biomarkers, remains a serious challenge. Prostate-specific antigen (PSA) widely recognized as bioma...